By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology and Flagship Biosciences today announced a service partnership to enable tissue translational biomarker development, validation, and application to support new drug development.

The new offering combines Expression's expertise in multiplex tissue proteomic assays using frozen formalin, paraffin-fixed tissues with Flagship's pathology expertise.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.